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The combination of ﬁlgrastim (G-CSF) and plerixafor is currently approved for mobilizing peripheral blood progenitor cells
in patients with non-Hodgkin lymphoma and multiple myeloma undergoing autologous peripheral blood hematopoietic cell
transplantation. However, chemotherapy and G-CSF-based mobilization remains a widely used strategy for peripheral blood
progenitor cell collection. In this paper we describe our experience from two North American transplant centers in a series of
patients who received salvage plerixafor while failing chemotherapy and G-CSF mobilization. Patients received a median of two
doses of plerixafor salvage upon failure to mobilize adequate number of peripheral blood progenitor cells at neutrophil recovery.
The use of plerixafor was associated with a 2.4-fold increase in peripheral blood CD34+ cell count and 3.9-fold increase in total
CD34+cellyield.Allpatientswereabletocollect≥ 2×106 CD34+cells/kgwiththisapproach.Theseresultsweremorepronounced
in patients with a higher CD34+ cell count at the time of the ﬁrst plerixafor dose. Interestingly, peripheral blood white blood cell
count was not shown to correlate with a response to plerixafor. Our results provide safety and eﬃcacy data for the use of plerixafor
in patients who are destined to fail chemomobilization.
1.Introduction
Autologous peripheral blood hematopoietic cell transplanta-
tion (auto-PBHCT) is a well-established therapeutic option
for patients with a variety of hematologic malignancies.
Mobilization of peripheral blood progenitor cells (PBPC) for
auto-PBHCT can be accomplished by using cytokines, most
commonly granulocyte-colony stimulating factor (G-CSF),
either alone or in combination with chemotherapy (e.g.,
cyclophosphamide, etoposide, cytarabine, etc.) or plerixafor
[1, 2]. Recently reported phase III studies have also shown
superiorityofthecombinationofG-CSFwithplerixaforover
G-CSF alone for mobilizing PBPC in patients with non-
Hodgkin lymphoma (NHL) and multiple myeloma (MM)
[3, 4].
Plerixafor acts by selective and reversible antagonism of
CXCR4 on CD34+ hematopoietic stem cells (HSC). This
results in disruption of its interaction with CXCL12 (for-
mallySDF1)onbonemarrowstromalcells,thatcausearapid
release of stem and progenitor cells from bone marrow into
peripheral blood. While plerixafor-based PBPC mobilization
can circumvent the need for chemotherapy to mobilize
CD34+ PBPCs, to our knowledge no prospective trials
comparing plerixafor plus G-CSF to chemomobilization
have been published to date. Limited data on murine models
suggest that a combination of plerixafor and chemotherapy
may be more eﬀective than the use of plerixafor alone for
PBPC mobilization [5].
Despite the promising results of plerixafor and G-CSF
for PBPC mobilization in patients with MM and NHL2 Journal of Oncology
[3, 4, 6–8], the use of chemotherapy and G-CSF-based
regimens to mobilize PBPC remains standard practice in
many transplant centers. This decision is often inﬂuenced
by a desire to improve collection yield, reduce mobilization
failures especially in patients who are elderly, heavily pre-
treated, and have poor bone marrow cellularity, and/or as
an attempt to provide disease control [9–11]. Limited data
are available on the preemptive use of plerixafor salvage in
patients failing to collect adequate numbers of PBPC with
chemotherapy and G-CSF-based mobilization [12–14], and
this topic has been reviewed recently [15]. Herein we report
our experience from two North American transplant centers
in a series of patients who received plerixafor salvage while
failing chemotherapy and G-CSF mobilization.
2. Methods
For patients undergoing chemotherapy and G-CSF-based
mobilization, it is standard operating procedure at both
transplant centers to measure peripheral blood CD34+ cell
count daily when the patient’s white blood cell (WBC) count
recovers to ≥4,000/µL or from day +12 (after chemotherapy)
onwards (whichever occurs ﬁrst). Apheresis is initiated when
the peripheral blood CD34+ cell count is ≥10/µL. Patients
destined to fail PBPC chemomobilization were deﬁned as
(i) those with a peak peripheral blood CD34+ cell count
of <10/µL following WBC count recovery (WBC count of
≥4,000/µL) after chemotherapy-induced nadir or (ii) those
who failed to collect at least ≥1 × 106 CD34+ cells/kg after
two apheresis sessions. In these patients failing chemomobi-
lization, we administrated plerixafor at a dose of 0.24mg/kg
subcutaneously 10 hours prior to apheresis in conjunction
with G-CSF (10µg/kg), as a preemptive salvage strategy. All
collections were performed with a COBE Spectra Apheresis
System (CaridianBCT, Lakewood, CO), by processing three
to four blood volumes. It is the institutional policy at both
transplant centers to routinely target collection of 5 × 106
CD34+ cells/kg. Determination of peripheral blood CD34+
cell count and CD34+ cell content of the apheresis product
was performed at the Georgia Health Sciences University
HLA Laboratory and West Virginia University Hospitals
Flow Cytometry Laboratory. The BD FACSCanto II ﬂow
cytometer, (Becton Dickinson, San Jose, CA) was used for
all analyses. After red blood cell lysis, washed samples
were used for CD34+ enumeration with PE-labeled, 8G12
clone, immunoglobulin G1 (Becton Dickinson, San Jose,
CA) based on International Society of Hematotherapy and
Graft Engineering (ISHAGE) guidelines. The ﬁnal products
were cryopreserved in 10% DMSO using a controlled rate
freezer and stored in liquid nitrogen. Successful mobilization
w a sd e ﬁ n e da sat o t a lo f≥2 × 106 CD34+ cells/kg patients
body weight in the ﬁnal product. Data was collected on
mobilization and transplant outcomes through an electronic
data base, prospectively maintained at each participating
institution and analyzed utilizing SPSS version 13.0.
3. Results
Patient characteristics and transplantation outcomes of 16
patients who were failing chemomobilization (as deﬁned
above) and received preemptive plerixafor are summarized
in Table 1. The median age was ﬁfty-six years. Patients had
received a median of two lines of therapies (range 1–3) prior
to PBPC mobilization. After recovering from chemotherapy-
induced count nadir (i.e., WBC ≥ 4000/µL), 15 patients had
a peak peripheral blood CD34+ cell count of <10µL. Five
patients underwent at least 2 sessions of apheresis but were
unable to collect ≥1 million CD34+ cells/kg. These patients
subsequently received a median of two doses of plerixafor
salvage (range 1–8). The median number of apheresis
sessions was 3.5 (range 2–7), and the median number of
CD34+ cells collected was 3.9 × 106 cells/kg (range 2.4–7.8).
Utilizing a cutoﬀ of ≥2 × 106 CD34+ cells/kg, all patients
who received plerixafor had a successful collection. Nineteen
percent of the patients were able to collect ≥5 × 106 CD34+
cells/kg. Three patients (one with Hodgkin lymphoma
and two with NHL) required more than four doses of
plerixafor, but all eventually collected ≥2 × 106 CD34+
cells/kg. The median peak peripheral blood CD34+ cell
count prior to plerixafor administration was 3.5/µL( r a n g e
0–15) and increased to 6/µL (range 2–47) after the ﬁrst
dose of plerixafor (P = 0.03). 93% of the patients had a
peak peripheral blood CD34+ cell count of <10/µLb e f o r e
plerixafor salvage. Four patients had a peak peripheral blood
CD34+cellcountof≤1/µLbeforeplerixaforsalvage.Kinetics
of peripheral blood CD34+ cell and WBC count changes
after each dose of plerixafor for these 4 patients is shown in
Table 2. After transplantation, the median time to neutrophil
and platelet engraftment was 10 days (range 9–15) and 20
days (range 9–29), respectively.
In order to identify predictors of response to plerixafor
salvage, correlation analyses were performed on a variety
of factors. As expected, patients with a higher peripheral
blood CD34+ cell count at the time of the ﬁrst plerixafor
dose had a higher magnitude of change in their peripheral
blood CD34+ cell counts (r2 = 0.58, P = 0.01). Only
three patients had a CD34+ cell count of ≥10/µL before the
ﬁrst dose of plerixafor, and their median increase was 18/µL
compared to 6/µL for patients who had peripheral blood
CD34+cellcountsof<10/µLhowever,thisdiﬀerencewasnot
statistically signiﬁcant (P = 0.3). We did observe a positive
correlation between peak peripheral blood CD34+ cell count
before the ﬁrst dose of plerixafor and the total number of
CD34+ cells collected at apheresis (r2 = 0.62; P = 0.01). Of
the 41 collections with plerixafor, the mean CD34+ cell dose
collected was 0.79 × 106 CD34+ cells/kg from 25 collections
in patients with a peripheral blood CD34+ cell count <10/µL
versus 2.09 × 106 CD34+ cells/kg from 16 collections in
patients with a CD34+ cell count greater than 10/µL( P =
0.001). Correlation analyses were performed in order to
deﬁne an optimal cutoﬀ of WBC count that can be used as a
marker for the initiation of plerixafor salvage, which showed
that WBC count had no correlation with a change in CD34+
cell count after the ﬁrst dose of plerixafor (r2 =− 0.21,
P = 0.41). Utilizing the median WBC count of 32/µL at the
timeofadministrationofplerixaforinourpatients,wefound
that we were able to collect a higher number of CD34+ cells
in patients who had a WBC count ≤32/µLa sc o m p a r e dt oJournal of Oncology 3
Table 1: Baseline characteristics and mobilization outcomes (N = 16).








Mobilization chemotherapy regimens 69% cyclophosphamide2
31% others3





Median number of prior therapies (range) 2 (1–3)
Prior radiation therapy 19%
Median number of days of G-CSF administration after chemotherapy prior to the administration of
plerixafor (range) 12 (7–21)
Median number of days to plerixafor administration after chemotherapy (range) 16 (12–25)
Mean white blood cell count (/µL) at the time of starting plerixafor Therapy (range) 13.4 (4.1–25.2)
Mean absolute neutrophil count (/µL) at the time of starting plerixafor Therapy (range) 11.7 (3.5–20.7)
Median peripheral blood CD34+ cell count (/µL) at the time of starting plerixafor therapy (range) 3.5 (0–15)
Median peripheral blood CD34+ cell count (/µL) at the time of starting apheresis (range) 8.5 (2–30)
Median number of plerixafor doses (range) 2 (1–8)
Median number of apheresis sessions (range) 3.5 (2–7)
Median number of CD34+ cells (×106 cells/kg) collected prior to starting plerixafor (range) 0 (0–3.13)
Median number of CD34+ cells (×106 cells/kg)collected 3.9 (2.4–7.8)
Percentage of patients with >2 × 106 cells/kg CD34+ cells collected 100%
Percentage of patients with >5 × 106 cells/kg CD34+ cells collected 19% (3/16)
Median increase in CD34+ cell count (/µL) after ﬁrst dose of plerixafor (range) 6.5 (1–35)
1Other diagnoses included Hodgkin lymphoma = 2 and Ewing sarcoma = 1.
2Cyclophosphamide dose = 3-4gm/m2 intravenously.
3Other chemotherapies included ICE (ifosfamide, carboplatin and etoposide), Hyper-CVAD (cyclophosphamide, vincristine, doxorubicin and dexametha-
sone), and D-PACE (dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide).
Table 2: Peripheral blood CD34+ cell and WBC count kinetics in response to plerixafor salvage in patients with extremely low baseline
CD34+ cell counts.
PB counts
















Patient #1 WBC 28.5 25.8 24.7 27.3 43.3
C D 3 4 + 11124
Patient #2 WBC 14 22.6 26.2 28.9 31.3 34.1 38.4 46.1
C D 3 4 + 1224467 1 1
Patient #3 WBC 4.1 10.6 14.7 14.8 17.1 18.6 20 22.7 27
C D 3 4 + 03433896 1 2
Patient #4 WBC 19.4 51.6 60.8 58.8 58.1 66.9 80.1
C D 3 4 + 03244 1 3 1 3
P = plerixafor; PB = peripheral blood; WBC = white blood cell count.4 Journal of Oncology
those with a WBC count >32/µL (1.67 × 106/kg versus 0.8 ×
106/kg, P = 0.02 resp.).
4. Discussion
Our limited multicenter outcomes data suggest that the
addition of plerixafor as a preemptive salvage may rescue
patients who are destined to fail chemotherapy and G-CSF-
based PBPC mobilization. In our series we used plerixafor
salvage to rescue an otherwise failed attempt for chemo-
mobilization, which contrasts with prior studies where
plerixafor was used to remobilize patients who had failed
prior mobilization attempts [16]. This is also in contrast
to studies where plerixafor was routinely given to patients
undergoing chemomobilization [17].
In our series plerixafor was given after recovery from
chemotherapy-induced count nadir (median of 11.5 days
after chemotherapy) and resulted in successful CD34+ cell
collection in all patients, who were otherwise likely to fail
chemomobilization.InterestinglypatientswithaWBCcount
of ≤ 32/µL were able to collect a higher number of CD34+
cells. This is in contrast to earlier data [12–15] that indicated
limited eﬃcacy of plerixafor in patients with a lower WBC
count. This discrepancy can be a reﬂection of the decreased
eﬃciency of the collection process in patients with a higher
WBC count or possibly a reﬂection of timing of plerixafor
administration. Generally a CD34+ cell count of 10–13/µL
is used as a cutoﬀ for initiating apheresis following cytokine
only, cytokine plus plerixafor, or chemomobilization in
majority of transplant centers in the country. The median
CD34+ cell count of our patients was only 3.5/µL with 82%
less than 10/µL at the time of the ﬁrst plerixafor dose, and all
patients were able to collect a minimum of 2 × 106 cells/kg.
However, a valid cutoﬀ for peripheral blood CD34+ cell
counttoinitiateapheresiswhenplerixaforisusedasasalvage
for failed chemomobilization is unknown.
Patient characteristics and institutional preference will
likely continue to inﬂuence the choice for mobilization strat-
egy in patients undergoing an auto-PBHCT [7]. While no
prospective data are available to demonstrate better eﬃcacy
or cost eﬀectiveness of plerixafor-based mobilization over
chemotherapy-basedmobilization[18],ourpreliminarydata
provide safety and eﬃcacy data for plerixafor salvage to res-
cuepatientsfailingchemotherapy-basedPBPCmobilization.
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